New drug may tame Life-Threatening reactions to cancer immunotherapy
NCT ID NCT04975555
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma, multiple myeloma, and leukemia. About 30 participants will receive siltuximab when they develop these side effects. The goal is to see if the drug helps resolve symptoms faster and reduce complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.